Michael Grippi is a Respiratory physician affiliated with Good Shepherd Penn Partners. OpenAlex indexes 25 publications with 1,120 citations (h-index 10).
Overview
Scholarship
indexed output and impact (OpenAlex)Publications indexed by OpenAlex. Counts exclude supporting files.
Citations across these publications.
H-index from these publications.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Medicare prescribing footprint (2020)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Respiratory
100%Corticosteroid100%Trelegy Ellipta100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 1985–1987 per NIH RePORTER. The latest:
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Functional Outcomes, Goals, and Goal Attainment among Chronically Critically Ill Long-Term Acute Care Hospital Patients
Annals of the American Thoracic Society
2021 - Respiratory Microbiome Disruption and Risk for Ventilator-Associated Lower Respiratory Tract Infection
Clinical Infectious Diseases
2021 - Comparison of Respiratory Microbiome Disruption Indices to Predict VAP and VAE risk at LTACH Admission
Infection Control and Hospital Epidemiology
2020 - 1209. Impact of Respiratory Staphylococcus aureus Abundance on Risk for Ventilator-Associated Pneumonia During Long-Term Care
Open Forum Infectious Diseases
2020 - Impact of Diagnosed and Undiagnosed Respiratory Pseudomonas on VAP and VAE During Long-Term Acute Care
Infection Control and Hospital Epidemiology
2020
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Fernando Martinez, MD
University of Massachusetts Chan Medical School
Ronald Crystal, MD
Weill Cornell Medicine
Bartolome Celli, MD
Brigham and Women's Hospital
Richard Casaburi, MD
University of California, Los Angeles
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”